Klinik für Gyäkologie und Geburtshilfe Städtisches Klinikum Solingen, Gotenstr. 1, 42653 Solingen, Germany.
Expert Opin Biol Ther. 2011 Mar;11(3):395-403. doi: 10.1517/14712598.2011.553598. Epub 2011 Jan 18.
Ovarian cancer (OC) is the fifth most common cancer in women. Unfortunately, more than 70% of cases are detected at an advanced stage with a risk of recurrence, after front line therapy, of over 75%. The need for new therapeutic strategies is extremely high.
The development status and the possible role of specific immunotherapy of abagovomab are discussed in the context of the possible therapeutic options for maintenance therapy in advanced OC. An overview of abagovomab, generation and mechanism of action, Phase I/II results and the status of the Phase II/III ongoing trial is given.
Abagovomab stimulates the humoral immune response and the cell-mediated immune response in the studies conducted to date. In the proof of concept (POC) study abagovomab prolonged overall survival in those OC recurrent patients who showed an immune response. Abagovomab has an excellent safety and tolerability profile. These characteristics make abagovomab an optimal candidate for a maintenance treatment for OC patients after frontline therapy. The final results of the Phase II/III pivotal study evaluating abagovomab in this setting will be available in the first half of 2011.
卵巢癌（OC）是女性中第五种最常见的癌症。不幸的是，超过 70%的病例在晚期被发现，一线治疗后复发的风险超过 75%。因此，对新的治疗策略的需求极高。
在高级 OC 维持治疗的可能治疗方案的背景下，讨论了 abagovomab 的开发状况和特定免疫疗法的可能作用。概述了 abagovomab 的发展、作用机制、I/II 期结果以及正在进行的 II/III 期试验的现状。
迄今为止进行的研究表明，abagovomab 可刺激体液免疫反应和细胞介导的免疫反应。在概念验证（POC）研究中，abagovomab 延长了显示免疫反应的 OC 复发性患者的总生存期。abagovomab 具有极佳的安全性和耐受性。这些特性使 abagovomab 成为一线治疗后 OC 患者维持治疗的理想候选药物。评估 abagovomab 在该环境下的 II/III 期关键研究的最终结果将于 2011 年上半年公布。
